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1. Introduction
   Peroxisome proliferators-activated receptors γ (PPARγ) is a 
ligands-activated nuclear transcription factor. Activated PPARγ 
binds to the peroxisome proliferator responsive element in the 
promoter of target gene to regulate gene expression[1,2]. For the 
past few years, PPARγ has been considered as a well-known anti-
aging molecule[3,4]. Activated PPARγ plays a role in regulating 
adipocyte differentiation and lipid metabolism, improving 
insulin resistance, inhibiting inflammatory reaction[5] and up-
regulating longevity gene expression such as Klotho[6]. Previous 
studies reported that PPARγ inactivation by phosphorylation was 
observed in many kinds of tissues, such as kidney[7], cerebral 
cortex[8] and fat[9], suggesting that PPARγ phosphorylation 
may play an important role in the initiation and development of 
aging and leads to functional disorder and aberrant expression 
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Objective: To investigate the expression of phosphorylated peroxisome proliferators-activated 
receptor γ (p-PPARγ) in the aging thoracic aorta of spontaneously hypertensive rat (SHR) and 
the inhibitory effect of rosiglitazone on the phosphorylation of PPARγ.
Methods: 16, 32 and 64 week-old Wistar-Kyoto rats (WKY) and SHR were randomly and 
respectively divided into WKY, SHR and SHR+rosiglitazone group (9 in each group). The rats 
in SHR+rosiglitazone group were treated with rosiglitazone (5 mg/kg, intragastrically) for 56 
d, whereas normal saline was applied in WKY and SHR groups. Systolic blood pressure (SBP) 
of rats was measured by tail cuff method. Histopathological damage of thoracic aorta was 
analyzed using Hematoxylin-Eosin (HE) staining. Immunohistochemical staining and western 
blot were performed to test the level of p-PPARγ protein in the thoracic aorta arising from each 
group.
Results: The SBP in 16, 32 and 64 week-old SHR were significantly higher as compared with 
those in matched WKY rats (P<0.05, respectively). HE staining showed increased content of 
smooth muscle cell, wrinkled lining endothelium and increased thickness of internal elastic 
lamina in the thoracic aorta of SHR. Immunohistochemical staining and western blot indicated 
that the levels of p-PPARγ in the thoracic aorta arising from SHR were obviously higher than 
those in the thoracic aorta arising from WKY rats (P<0.05, respectively). Importantly, the high 
SBP, histopathological abnormalities of the thoracic aorta and elevated p-PPARγ expression 
were prominently abrogated by rosiglitazone treatment in SHR (P<0.05, respectively). 
Furthermore, the SBP, histopathological abnormalities of the thoracic aorta and p-PPARγ 
expression were positively correlated with age in SHR (P<0.05, respectively).
Conclusions: The PPARγ phosphorylation was observed in the thoracic aorta of SHR and 
its expression was increased by the increase of age. Furthermore, rosiglitazone inhibited the 
PPARγ phosphorylation and suppressed vascular aging in SHR.
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of downstream target gene. Vascular aging can change the 
threshold and severity of cardiovascular diseases including 
hypertension[10]. It is an independent risk factor for the increasing 
incidence of hypertension with older age[10,11]. However, whether 
PPARγ inactivation and the degree of PPARγ phosphorylation are 
presented during hypertension related vascular aging remains 
undetermined.
   Recently, Choi et al. reported that cyclin-dependent kinase 5 
(Cdk5) could lead to PPARγ phosphorylation in adipocytes and 
subsequently result in functional disorder and aberrant expression 
of obesity related gene. PPARγ phosphorylated by Cdk5 is 
inhibited by rosiglitazone, a PPARγ agonist, in vitro and in vivo[12]. 
Furthermore, the inhibitory effect is independent of canonical 
receptor transcriptional activation pathway. These results indicate 
that rosiglitazone may inhibit PPARγ phosphorylation in vascular 
aging of hypertension patients. In this study, 16, 32 and 64 week-
old spontaneously hypertension rats (SHR) were treated with 
rosiglitazone. We aimed to investigate PPARγ phosphorylation in 
the thoracic aorta of SHR during vascular aging and explore the 
inhibitory effect of rosiglitazone on PPARγ phosphorylation.
2. Materials and methods
2.1. In vivo experiments 
   The 16, 32 and 64 week-old SHR (n=54) and Wistar-Kyoto 
(WKY) rats (n=27) were purchased from Shanghai Slack 
Laboratory Animal Co., LTD (Permit number: SCXK: 2007-
0005, Shanghai, China) and cultured in the Centre of Laboratory 
Animals, Medical College of Xi’an Jiaotong University. Rats were 
housed in sterilized cages (2 rats/cage) at a constant temperature 
(23 °C) and humidity and fed a regular autoclaved diet with water 
ad libitum[13]. Rats were respectively divided into WKY (n=9), 
SHR (n=9) and SHR+rosiglitazone groups (n=9). Rats in the 
SHR+rosiglitazone group were treated with rosiglitazone (5 mg/
kg) daily for 8 weeks through intragastric administration. While, 
rats in the WKY and SHR groups were treated with the same 
volume of saline. Blood pressure measurement was performed 
after treatment. After treatment, systolic blood pressure (SBP) was 
measured using tail cuff method as previous described[14]. All rats 
were sacrificed by cervical vertebra dislocation under anesthesia 
with ether and the thoracic aorta tissues were excised and 
prepared for routine pathological examination with Hematoxylin-
Eosin (HE) staining[13]. Some thoracic aorta tissues (n=3) were 
subjected to immunohistochemical analysis, and some (n=6) were 
homogenized and the proteins extracted for immunoblotting. All 
animal protocols were approved by the Institutional Animal Care 
and Use Committee of Xi’an Jiaotong University.
2.2. Immunohistochemical staining
   Immunohistochemistry was performed on paraformaldehyde-
fixed paraffin sections with streptavidin peroxidase conjugated 
method to detect the positive expression of phosphorylated PPARγ 
(p-PPARγ) in the aortas of rats according to the manufacturer’s 
instructions (Zhongshan Golden Bridge Biotechnology Ltd. Co., 
Beijing, China). The sections of thoracic aorta were routinely 
dewaxed and antigen retrieval in citrate buffer (0.01 mol/L, pH 
6.0). The sections were subsequently blocked using 10% goat 
plasma and incubated using p-PPARγ (Ser 273; Beijing Bioss 
Biological Technology Ltd. Co., Beijing, China) (1:600) primary 
antibody at 4 ˚C overnight. Biotinylated secondary antibodies were 
used to detect the primary antibody. The sections were visualized 
with diaminobenzidine (Wuhan Boster Biological Engineering 
Ltd. Co., Wuhan, China) and counterstained with hematoxylin, 
then dehydrated in alcohol and xylene and mounted onto glass 
slides. Phosphate buffer solution was used as primary antibody for 
negative control.
2.3. Western blot
   The total proteins were isolated from thoracic aorta and 
measured using Protein Quantitative Reagent Kit-BCA Method 
(Beijing Bioss Biological Technology Ltd. Co.). After protein 
denaturation at 95 °C, proteins were separated using 8% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis and transferred 
into the nitrocellulose filter. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (G8140; US Biological, Swampscott, 
MA, USA) (1:5 000) and p-PPARγ (1:800) primary antibodies 
were used in the immunoblotting assays. Horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit secondary antibodies 
(Bio-Rad, Hercules, CA, USA) were used at a 1:1 000-1: 5 000 
dilution and detected using a Western Blotting Luminol Reagent 
(sc-2048; Santa Cruz Biotechnology), as described in previous 
study[15].
2.4. Statistical analysis
   The data were analyzed using the SPSS statistical package for 
Windows Version 13 (SPSS, Chicago, IL, USA). Results were 
expressed as mean±SEM. Levene test and Shapiro-Wilk test were 
performed to determine the homogeneity test for variance and 
normality test, respectively. Significance was established using 
One-way ANOVA and LSD-t test when appropriate. Difference was 
considered significant when P<0.05.
3. Results
3.1. The SBP of SHR and WKY rats with different age
   As shown in Figure 1, the SBP in 16, 32 and 64 week-old 
SHR were significantly higher than those in matched WKY 
rats (P<0.05). However, the SBP in rosiglitazone treated SHR 
were obviously lower as compared with those in matched SHR 
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(P<0.05). In SHR, 64 week-old rats showed the highest SBP as 
compared with either 32 week-old or 16 week-old rats (P<0.05, 
respectively). But 16 week-old SHR exhibited the lowest SBP as 
compared with 32 week-old rats (P<0.05). Comparison of SBP in 
16, 32 and 64 week-old WKY rats, the highest SBP was observed 
in 64 week-old rats (P<0.05, respectively, Figure 2), while 16 
week-old rats showed the lowest SBP (P<0.05, respectively, 
Figure 2).
3.2. The structure of thoracic aorta in SHR and WKY rats 
with different age
   As shown in Figure 3, HE staining showed the layer of elastic 
fibers was no big change, but exhibited increased content of 
smooth muscle cell, wrinkled lining endothelium and increased 
thickness of internal elastic lamina in the thoracic aorta of SHR. 
These histopathological changes were worsened by the increase 
of age. The histopathological changes in SHR+rosiglitazone group 
were less than those in SHR group. WKY group only showed 
increased layer of elastic fibers with the increase of age. But other 
histopathological changes were not observed in WKY group.
3.3. The expression of p-PPARγ in the thoracic aorta of rats
   The thoracic aortas arising from rats in different groups were 
subjected to immunostaining for p-PPARγ. As shown in Figure 
4, our results found that p-PPARγ signal was increased by the 
increase of age in both SHR and WKY rats. P-PPARγ signal in SHR 
group was obviously higher than that in matched WKY group. 
However, SHR+rosiglitazone group showed less p-PPARγ signal 
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Figure 1. SBP in different groups with different age.
The SBP in SHR group was significantly higher than that in WKY group. 
However, The SBP in SHR+rosiglitazone group was obviously lower than 
that in SHR group. Values are depicted as mean±SEM, n=9. *P<0.05 vs 
WKY group; #P<0.05 vs SHR group.
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Figure 2. SBP in SHR and WKY rats with different age.
The SBP in 64 week-old SHR was prominently higher than that in either 
32 or 16 week-old rats. While 16 week-old SHR showed the lowest SBP. 
Similarly, The SBP in 64 week-old WKY rats was significantly higher than 
that in either 32 or 16 week-old rats. While 16 week-old WKY rats showed 
the lowest SBP. Values are depicted as mean±SEM, n=9. *P<0.05 vs 16 
week; #P<0.05 vs 32 week.
Figure 3. HE staining of the thoracic aorta of rats in different groups.
The histopathological changes were worsened by the increase of age in 
SHR group. The histopathological changes in SHR+rosiglitazone group 
were less than those in SHR group. However, WKY group showed slight 
histopathological changes. Original magnification ×100.
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Figure 4. Immunohistochemical analyses of p-PPARγ in the thoracic aorta 
of rats in different groups.
The p-PPARγ signal was up-regulated by the increase of age in both SHR 
and WKY groups. The p-PPARγ signal in SHR group was higher than that in 
WKY group. However, SHR+rosiglitazone group showed a weak p-PPARγ 
signal as compared with SHR group. Original magnification ×400.
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as compared with SHR group. As shown in Figures 5A and 5B, 
western blot analysis indicated that the levels of p-PPARγ in the 
thoracic aorta isolated from 16, 32 and 64 week-old SHR were 
significantly higher than those in matched WKY rats (P<0.05, 
respectively). Whereas, the levels of p-PPARγ in the thoracic aorta 
arising from rosiglitazone treated SHR were obviously lower than 
those in matched SHR (P<0.05, respectively). In SHR, 64 week-
old rats showed the highest p-PPARγ expression as compared with 
either 32 week-old or 16 week-old rats (P<0.05, respectively). 
But 16 week-old SHR exhibited a lower p-PPARγ expression 
as compared with 32 week-old rats (P<0.05). Comparison of 
p-PPARγ expression in 16, 32 and 64 week-old WKY rats, the 
highest p-PPARγ expression was observed in 64 week-old rats 
(P<0.05, respectively, Figure 5B), while 16 week-old rats showed 
the lowest p-PPARγ expression (P<0.05, respectively, Figure 5B).
Figure 5. Western blot analysis of p-PPARγ protein in the thoracic aorta of 
rats in different groups.
A: Representative western blot analysis of p-PPARγ expression in the 
thoracic aorta of rats in different groups; B: Quantification of the data 
revealed that p-PPARγ expression in SHR group was higher than that in 
WKY group. However, SHR+rosiglitazone group showed a less p-PPARγ 
level as compared with SHR group. Values are depicted as mean±SEM, n=6. 
*P<0.05 vs WKY group; #P<0.05 vs SHR group.
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4. Discussion
   Vascular aging is mainly characterized as characteristic 
remodeling of the structure and function by the increase of age, 
which is an independent risk factor for promoting the incidence 
of hypertension[10,11]. In this study, SBP were measured using 
a tail cuff method. Our data indicated that the SBP in SHR 
was elevated by the increase of age. HE staining showed that 
the histopathological changes including increased content of 
smooth muscle cell, wrinkled lining endothelium and increased 
thickness of internal elastic lamina in the thoracic aorta of SHR 
were worsened by the increase of age. These results indicate that 
vascular aging is observed in the thoracic aorta of SHR. PPARγ acts 
as a nuclear transcription factor for regulating several senescence-
associated genes[3-6]. PPARγ phosphorylation is an important 
post-transcriptional modification and it has been found in many 
aging diseases[7-9]. However, whether PPARγ phosphorylation 
is presented in vascular aging induced hypertension has not 
been investigated. We, for the first time, approved that p-PPARγ 
was observed in the thoracic aorta of 16, 32 and 64 week-old 
SHR by the increase of age, which was consistent with vascular 
aging in the thoracic aorta. These results suggest that PPARγ 
phosphorylation is enhanced during hypertension related vascular 
aging. But the priority of PPARγ phosphorylation or vascular aging 
needs to be further confirmed.
   Different phosphorylated residues of PPARγ in different cells and 
under different stimulations exert different biological effects[16]. 
Mitogen-activated protein kinases induce the phosphorylation of 
PPARγ on Ser112 and inhibit PPARγ activity[17-19]. However, cyclin-
dependent kinase 7 (Cdk7) and Cdk9 lead to phosphorylation of 
PPARγ on Ser112 and increase PPARγ activity[20,21]. Otherwise, 
Cdk5 mediates Ser273 phosphoryaltion, which is located at hinge 
region between PPARγ DNA binding domain and ligand binding 
domain, to regulate target gene expression[12]. Our studies just 
detected the level of p-PPARγ with Ser273 phosphorylation. Thus, 
the level of p-PPARγ with Ser112 phosphorylation still needs 
further studies. Previous studies have approved that PPARγ agonist, 
rosiglitazone, inhibits Cdk5 mediated phosphorylation of PPARγ 
on Ser273 in adipocytes and is independent of canonical receptor 
transcriptional activation signaling pathway[12]. Our studies further 
confirmed that rosiglitazone inhibits the phosphorylation of PPARγ 
on Ser273 in the thoracic aorta of SHR. But further researches are 
needed to confirm that the effect is mediated by Cdk5 pathway or 
not. Otherwise, PPARγ functions as a nuclear transcription factor 
for regulating many target gene expression. Whether rosiglitazone 
binds to PPARγ and regulates phosphorylation related target gene 
expression to inhibit PPARγ phosphorylation still need to be 
approved.
   In conclusion, PPARγ phosphorylation is observed in the 
thoracic aorta of SHR during vascular aging. Furthermore, the 
level of p-PPARγ protein is up-regulated by the increase of age. 
Rosiglitazone inhibits PPARγ phosphorylation and vascular aging. 
These results contribute to revealing the mechanisms involved in 
hypertension vascular aging.
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